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Abstract
Background: Bilirubin-related neurotoxicity is an important clinical issue in very low birthweight (VLBW) infants, and the
existing literature is inconsistent.
Objective: To analyze the relationship between maximal serum unconjugated bilirubin levels (SBL) and neurodevelop-
mental outcome at 2-year corrected age in VLBW infants.
Methods: Phototherapy was initiated in all infants born before 33 weeks of gestation, according to Maisels’
recommendations. Neurodevelopmental assessment at 2-year corrected age was performed in all infants that survived.
SBLs collected during the first week of life were used to define three tertiles of max-SBL. The first tertile corresponded to
infants with the lowest max-SBL.
Results and Conclusions: A total of 724 infants were included in the study, and among them, 631 (87%) were evaluated at
two years old. The infants of the first tertile were younger and smaller than the infants of the other two tertiles, in
accordance with Maisels’ recommendations for very small infants. No difference in the risk of impaired functional outcome
among the three groups was observed. However, among infants weighing less than 1001 g, those in the third tertile had a
poorer neurodevelopmental prognosis as compared to those in the second tertile (adjusted odds ratio=6.8, 95% CI: 1.2–
36.7, p=0.03). Considering the results obtained, we propose 196 mmol/L (11.5 mg/dL) when birthweight varies between
1001 and 1500 g, and 170 mmol/L (9.9 mg/dL) when birthweight is less than 1001 g, as recommended max-SBLs (defined as
maximal levels of 95
th percentile curves of SBLs in infants with an optimal outcome). When Maisels’ recommendations were
applied, max SBLs were higher in 8% of infants weighing 1001–1500 g and in 15% of infants weighing less than 1001 g. Our
data seems to validate Maisels’ recommendations in the overall population of infants born before 33 weeks of gestation, but
not in infants weighing less than 1001 g.
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Introduction
Despite showing a potentially protective antioxidant effect,
unbound bilirubin is neurotoxic, and accumulates in the basal
ganglia and in numerous brainstem nuclei [1–3]. Indeed, a high
level of unbound bilirubin can lead to acute encephalopathy and
kernicterus, although good management can reduce the occur-
rence of these complications [1]. The management of bilirubin in
infants born before 35 weeks of gestation has been well-
documented [1]. However, little is known about hyperbilirubin-
emia in very low birthweight (VLBW) infants.
Premature infants are at a special risk of elevated bilirubin
production, lower hepatic conjugation, lower albumin binding
capacity and increased central nervous system sensitivity to
unbound bilirubin, depending on birthweight [3–4]. These factors
increase the risk of neurosensory injury, and cases of acute
encephalopathy have been reported in preterm infants with total
bilirubin levels lower than those usually reported at term [4–5].
Given these considerations, specific thresholds of bilirubin levels
for initiating phototherapy in premature infants have been
suggested [4,6–7].
Nevertheless, few studies have evaluated the neurodevelopmen-
tal benefits of these recommendations. A first work reported a
correlation between maximal total bilirubin level and disability at
2 years of age among VLBW infants, despite hyperbilirubinemia
treatment according to Maisels’ recommendations [7–8]. In
another study, O’Shea et al. recommended a threshold level of
86 mmol/L (5 mg/dL) of total bilirubin for starting phototherapy
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between maximal total bilirubin and neurodevelopmental out-
come at 12-month corrected age [9]. Two other studies reported
an association between maximal total bilirubin level and impaired
neurodevelopmental outcome in VLBW infants at 18- and 22-
month corrected ages [10–11], although the phototherapy
procedure was not specified. Oh et al. showed that an increasing
level of unbound bilirubin in unstable neonates was associated
with death and adverse neurodevelopmental outcome at 18 and 22
months of corrected age. Paradoxically, the authors found an
association between decreasing levels of total bilirubin and poor
outcome in stable infants [12]. Recently, Moll et al. reported the
cases of two extremely low birthweight (ELBW) infants with
kernicterus, and questioned whether current phototherapy guide-
lines are appropriate for high-risk ELBW infants [13].
Given the lack of validated recommendations regarding
phototherapy in VLBW infants, the aim of this study was to
assess the potential relationship between bilirubin levels during the
first days of life and neurological outcome in a cohort of preterm
infants reaching 2 years of age.
Methods
Study population and data collection
All surviving infants born before 33 weeks of gestation in Nantes
University Hospital (France) between January 2003 and December
2006 were enrolled in the LIFT cohort and included in this study.
The cohort was registered at the French CNIL (Commission
Nationale de l’Informatique et des Liberte ´s nu851117) ethics
committee in order to collect clinical data from patients’ records.
Specific approval to use the data in this study was obtained from
the Institutional Review Board of the University Hospital of
Nantes. The children’s parents provided written informed consent,
which was obtained in each case before inclusion in the LIFT
cohort and before using the data. All potential participants who
declined to participate or otherwise did not participate were not
disadvantaged in any way by not participating in the study. The
day of the birth was considered Day 1. Initial data were
prospectively collected. During hospitalization, phototherapy was
started following Maisels’ recommendations [7], which were
described in a notebook for all clinicians. According to these
recommendations, phototherapy was started in infants with a
birthweight lower than 1500 g and with low serum unconjugated
bilirubin levels (SBLs). Biochemical data were collected from the
prospectively entered hospital biochemistry database. The child’s
file number allowed for linkage between biochemical and clinical
data. SBLs were collected for the first week of life, and the
maximal serum unconjugated bilirubin level (max-SBL) was
recorded for each child.
Patient assessment
After parental consent was obtained, the infants were enrolled
in our Loire Infant regional follow-up network [14] and evaluated
at 2-year corrected age. Neurodevelopmental assessment includ-
ed physical examination by a trained pediatrician and psycho-
motor evaluation by a psychologist. Neuromotor function was
regarded as non-optimal in cases of cerebral palsy or when milder
signs consistent with impaired independent walking were present
at 2-year corrected age. Psychomotor development was assessed
with the revised Brunet-Le ´zine test [15]. The test was performed
by a specialized psychologist and evaluated four developmental
areas: fine motor skills, social skills, language skills, and posture
and gross motor adaptation [16], allowing the calculation of four
separate scores plus an overall developmental score. Values lower
than 85 indicated a non-optimal psychomotor development. The
infants who were not able to take the Brunet-Le ´zine test because
their neurologic impairment was too severe were included in the
‘‘non-optimal psychomotor development’’ group. When a
psychological evaluation could not be conducted, outcome was
assessed with the Agesand Stages Questionnaire (ASQ)[17].This
parent-completed developmental questionnaire is divided into
five areas that assess a child’s development: communication, gross
motor skills, fine motor skills, problem solving and personal/
social skills. The ASQ has been recently validated by comparison
with the revised Brunet-Le ´zine test and with other formal
psychometric assessment tools [18–20]. An abnormal ASQ was
considered when patients did not meet at least two of the five
areas and defined non-optimal psychomotor development.
Children with non-optimal neuromotor and/or psychomotor
assessments were considered as having impaired functional
outcome.
Statistical analysis
Three tertiles of max-SBL were defined using SPSS 15.0
(Chicago, I). The infants from the first tertile constituted the
reference group. Functional outcome at 2 years of age was
analyzed as a binary variable. The analysis was conducted in four
steps. In the first step, the relationship between max-SBL tertiles
and clinical characteristics was analyzed. In the second step, the
Figure 1. Characteristics of the study population.
doi:10.1371/journal.pone.0030900.g001
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opmental outcome was assessed. The x
2 test, with Yates’
correction if necessary, and analysis of variance were used to
compare the characteristics of infants and 2-year outcome among
the three tertiles. In the third step, the association between max-
SBL and neurodevelopmental outcome was evaluated (crude
association). A logistic regression was performed to adjust for
confounding variables. Adjusted odds ratios (aOR) for neuromotor
and psychomotor impairment according to max-SBL were
calculated. In the fourth step, the relationship between max-SBL
and 2-year neurodevelopmental outcome was assessed in three
subpopulations: infants with birthweight under 1001 g, between
1001 and 1500 g, and over 1500 g. For all subpopulations, three
progressive curves of SBLs were created, which represented the
median distribution of SBLs in the first week of life for each tertile.
We defined a recommended max-SBL for each subpopulation,
which consisted of the maximal level of the 95
th percentile curve of
SBLs in children with a normal neurodevelopmental outcome at 2
years. The results were expressed as crude and aOR, including
95% confidence intervals (CIs), for adverse neurodevelopmental
outcome associated with increased max-SBL. Moreover, to
increase the sensibility of our analyses, we analyzed the correlation
between ASQ and max-SBL, adjusted for gestational age (GA), in
the overall population and in each subgroup according to
birthweight. All tests were two-tailed, and the significance level
was set at 0.05.
Table 1. Bilirubin determination and characteristics of preterm infants according to different tertiles of maximal serum non-
conjugated bilirubin level.
Characteristics
First Tertile
(N=227)
Second Tertile
(N=250)
Third Tertile
(N=247) p-value
Bilirubin determination
Number of serum non-conjugated bilirubin determinations per infant
during the first week of life, mean (SD)
2.7 (1.4) 4.5 (1.3) 4.6 (1.1) 0.001
Maximal serum non-conjugated bilirubin level, mmol/L, mean (SD) 100.6 (35.7) 156.1 (9.5) 208.1 (33.5) 0.001
Age of maximal serum non-conjugated bilirubin determination in days, mean (SD) 3.8 (1.2) 4.4 (1.2) 4.5 (1.0) 0.001
Infants’ characteristics
Gestational age (GA)
24–26 weeks (%) 36 (15.9) 15 (6.0) 7 (2.8) 0.001
27–28 weeks (%) 60 (26.4) 51 (20.4) 25 (10.1)
29–30 weeks (%) 57 (25.1) 104 (41.6) 61 (24.7)
31–32 weeks (%) 74 (32.6) 80 (32.0) 154 (62.3)
Birthweight
,1001 g (%) 95 (41.9) 47 (18.8) 25 (10.1) 0.001
1001–1500 g (%) 77 (33.9) 147 (58.8) 84 (34.0)
.1500 g (%) 55 (24.2) 56 (22.4) 138 (55.9)
Small for GA (%) 47 (20.7) 18 (7.2) 22 (8.9) 0.001
Mothers’ characteristics
Health insurance for low financial income 17 (7.5) 12 (4.8) 7 (2.8) 0.07
Upper socio-demographic level 80 (35.2) 77 (30.8) 87 (35.2) 0.49
Pregnancy
Prenatal corticosteroid treatment (%) 167 (73.6) 171 (68.4) 177 (71.7) 0.45
Multiple pregnancies (%) 64 (28.2) 87 (34.8) 78 (31.6) 0.30
Cesarean section (%) 177 (78.0) 167 (66.8) 130 (52.6) 0.001
Premature rupture of membranes .24 h 22 (9.7) 31 (12.4) 38 (15.4) 0.17
Hypertension during pregnancy 34 (15.0) 35(14.0) 36 (14.6) 0.96
Neonatal hospitalization
Surfactant therapy (%) 121 (53.3) 125 (50.0) 102 (41.3) 0.25
Maternofetal sepsis (%) 38 (16.7) 38 (15.2) 38 (15.4) 0.88
Nosocomial sepsis (%) 68 (30.0) 56 (22.4) 43 (17.4) 0.005
Bronchopulmonary dysplasia (%) 18 (7.9) 5 (2.0) 7 (2.8) 0.002
Hemodynamic failure (%) 26 (11.5) 14 (5.6) 12 (4.9) 0.01
Patent ductus arteriosus requiring treatment (%) 51 (22.5) 34 (13.6) 18 (7.3) 0.001
Outcome at 2 years N=201 N=219 N=211
Optimal outcome (%) 163 (81.1) 185 (84.5) 182 (86.3) 0.35
Impaired functional outcome (%) 38 (18.9) 34 (15.5) 29 (13.7)
doi:10.1371/journal.pone.0030900.t001
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Study population and follow-up
Of the 964 preterm infants born before 33 weeks of gestation
during the four years of the study period, perinatal data was linked
with biological data for only 910 of the infants. Of these 910
infants, 71 died during hospitalization and 839 survived. Max-SBL
was significantly lower in the infants who did not survive (108662
vs. 152659 mmol/L, p=0.001, respectively). Among the 839
surviving infants, 732 were enrolled in the regional network. Eight
infants with genetic syndromes were excluded from the analysis. A
total of 724 infants were finally included in the analysis (Fig. 1).
There was no significant difference between infants who were
included (n=724) and who were not included (n=115) regarding
GA (29.762.0 vs. 29.962.0 weeks, p=0.27) and birthweight
(13406460 vs. 14006370 g, p=0.16). Max-SBL was significantly
lower in infants who were not included in the analysis
(130687 mmol/L vs. 156651 mmol/L; p=0.001, respectively).
Risk factors for elevated max-SBL
The total number of serum unconjugated bilirubin measure-
ments was 2,746 (Table 1). The infants in the two last tertiles had
significantly more blood analyses and a significantly greater max-
SBL than infants in the first tertile. Infants in the first tertile had a
significantly lower GA and lower birthweight than infants in the
other two tertiles (Table 1). Furthermore, nosocomial sepsis,
bronchopulmonary dysplasia, hemodynamic failure and patent
ductus arteriosus were significantly more frequent among the
younger and smaller infants of the first tertile. There was no
difference in the frequency of radiological assessments or
radiological findings between the infants in the different tertiles,
nor in the follow-up or outcome information.
Risk factors for impaired functional outcome
The results of the univariate analysis between neurological
outcome and the characteristics of preterm infants are presented in
Table 2. Impaired functional outcome was significantly associated
with characteristics of neonatal hospitalization and decreased as
GA and birthweight increased (p=0.001).
Max-SBL and neurodevelopmental outcome
Impaired functional outcome was 19%, 15% and 14% in the
first, second and third tertiles, respectively (p=0.35). Adjustments
for infant, mother, pregnancy and neonatal hospitalization
characteristics did not reveal any association between max-SBL
tertiles and neurodevelopmental outcome (Table 3). Additional
adjustment for radiological brain lesions provided similar results
(aOR for the second tertile: 1.0, 95% CI: 0.6–1.9, p=0.95; aOR
for the third tertile: 1.0, 95% CI:0.5–2.0, p=0.92). Moreover,
Max-SBL was not correlated with ASQ (n=537, R
2 adjusted for
GA=0.004, p=0.64).
In the subpopulation of 151 infants with birthweight ,1001 g,
neurological outcome tended to be different among the three
tertiles (p=0.05). Those with the most elevated max-SBLs (third
tertile) had a greater tendency for an impaired functional outcome
at 2-year corrected age (p=0.05) (Table 4). Moreover, after
adjustment for infant, mother, pregnancy, neonatal hospitalization
characteristics and radiological brain lesions, the infants in the
third tertile with a birthweight ,1001 g had a significantly more
elevated risk for impaired functional outcome than those in the
second tertile with a birthweight ,1001 g (aOR=6.8, 95%
CI:1.2–36.7, p=0.03). Max-SBL was not correlated with ASQ
(n=128, R
2 adjusted for GA=0.006, p=0.55). In contrast, we did
not observe any difference between tertiles among infants with
birthweight over 1000 g and Max-SBL. Moreover, Max-SBL was
not significantly correlated with ASQ in infants with birthweight
over 1500 g (n=185, R
2 adjusted for GA=0.005, p=0.56) and
tended to be correlated in infants with birthweight between 1001
and 1500 g (n=221, R
2 adjusted for GA=0.03, p=0.09).
Mean SBLs for the first week of life were compared to the 95
th
percentile curves of SBLs of infants with normal outcome at 2
years (Figure 2). Infants in the third tertile with birthweight under
1001 g presented a SBL curve that evolved relatively similarly to
the 95
th percentile curve of SBLs of infants with a normal
neurological outcome. The recommended max-SBLs (maximal
levels of 95
th percentile curves of SBLs of infants with an optimal
outcome) reached 170 mmol/L (9.9 mg/dL) when birthweight was
under 1001 g, and 196 mmol/L (11.5 mg/dL) when birthweight
varied between 1001 and 1500 g.
Table 2. Association between neonatal characteristics of 631
infants and non-optimal neurological outcome at 2-year
corrected age.
Variables OR (95% CI) p-value
Infants’ characteristics
Gestational age (GA)
24–26 weeks 3.8 (1.9–7.8) 0.001
27–28 weeks 2.4 (1.3–4.1)
29–30 weeks 1.2 (0.9–2.7)
31–32 weeks 1.0
Birthweight
,1001 g 2,8 (1.6–5.0) 0.001
1001–1500 g 1.6 (0.9–2.8)
.1500 g 1.0
Small for GA 3.2 (1.9–5.3) 0.001
Male 1.4 (0.9–2.2) 0.14
Mothers’ characteristics
Health insurance for low financial income 2.8 (1.4–5.9) 0.005
Upper socio-demographic level 0.8 (0.5–1.3) 0.47
Characteristics of pregnancy
Prenatal corticosteroid treatment 0.9 (0.6–1.5) 0.79
Multiple pregnancies 0.8 (0.5–1.3) 0.40
Cesarean section 1.4 (0.9–2.2) 0.19
Premature rupture of membranes .24 h 0.7 (0.4–1.3) 0.26
Hypertension during pregnancy 1.1 (0.6–2.1) 0.71
Characteristics of neonatal hospitalization
Surfactant therapy 1.94 (1.2–3.0) 0.003
Maternofetal sepsis 1.99 (1.2–3.3) 0.007
Nosocomial sepsis 1.81 (1.1–2.9) 0.010
Bronchopulmonary dysplasia 2.96 (1.3–6.6) 0.005
Hemodynamic failure 2.72 (1.4–5.2) 0.002
Patent ductus arteriosus requiring treatment 1.82 (1.1–3.1) 0.025
Cerebral radiologic assessment
No lesion 1.0 0.001
Intraventricular hemorrhage grade 1–2 1.14 (0.4–3.0)
Intraventricular hemorrhage grade 3–4 9.12 (2.0–41.7)
White matter lesions 8.31 (3.9–17.7)
Radiologic assessment not available 1.67 (0.8–3.4)
doi:10.1371/journal.pone.0030900.t002
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Our study of a large population-based cohort showed that
premature infants born before 33 weeks of gestation, and for whom
phototherapy was started in accordance with Maisels’ recommen-
dations, presented similar neurodevelopmental outcome at 2-year
corrected age, irrespective of the max-SBL recorded during their
first week of life. This study presents some limitations. One of them
is that it concerned a group of mixed and poorly comparable
premature infants born at 24 and 32 weeks of gestation. For this
reason, we also performed a subgroup analysis in infants with
birthweight under 1001 g. The infants at higher risk of impaired
neurodevelopmental outcome presented lower max-SBL, because
phototherapy was started at lower SBLs, according to Maisel’s
Table 3. Association between maximal serum non-conjugated bilirubin level and non-optimal neurological outcome at 2-year
corrected age (n=631).
Tertiles of maximal serum non-conjugated bilirubin levels and adjustment OR (95% CI) p-value
No adjustment
First tertile 1
Second tertile 0.8 (0.5–1.3) 0.36
Third tertile 0.7 (0.4–1.2) 0.16
Adjustment for infants’ characteristics
First tertile 1.0
Second tertile 1.0 (0.6–1.8) 0.95
Third tertile 1.1 (0.6–2.0) 0.80
Adjustment for infant, mother and pregnancy characteristics
First tertile 1.0
Second tertile 1.0 (0.6–1.7) 0.97
Third tertile 1.1 (0.6–1.9) 0.86
Adjustment for infant, mother, pregnancy and neonatal hospitalization characteristics
First tertile 1.0
Second tertile 1.0 (0.6–1.8) 0.96
Third tertile 1.1 (0.6–2.0) 0.82
Pregnancy characteristics included prenatal corticosteroid treatment, multiple pregnancies, hypertension during pregnancy, premature rupture of membranes .24 h
and cesarean section. Mother characteristics included health insurance for low financial income and upper socio-demographic level. Infant characteristics included GA,
birthweight, small for GA and gender. Neonatal hospitalization characteristics included surfactant therapy, maternofetal sepsis, nosocomial sepsis, bronchopulmonary
dysplasia, hemodynamic failure and patent ductus arteriosus requiring treatment.
doi:10.1371/journal.pone.0030900.t003
Table 4. Association between maximal non conjugated bilirubin level and non-optimal neurological outcome in 631 infants at 2-
year corrected age (subpopulations studies).
POPULATIONS N Crude OR (95% CI) p-value aOR (95% CI) p-value
Birthweight ,1001 g 151
First tertile 89 1 1
Second tertile 41 0.4 (0.1–1.1) 0.09 0.4 (0.1–1.5) 0.17
Third tertile 21 2.2 (0.8–5.8) 0.12 3.1 (0.8–11.4) 0.09
Birthweight from 1001 to 1500 g 268
First tertile 66 1 1
Second tertile 127 1.2 (0.5–2.7) 0.70 1.9 (0.7–5.0) 0.18
Third tertile 75 0.9 (0.3–2.4 0.76 1.6 (0.5–4.7) 0.42
Birthweight .1500 g 212
First tertile 46 1 1
Second tertile 51 1.3 (0.4–4.4) 0.67 1.5 (0.4–5.8) 0.53
Third tertile 115 0.8 (0.3–2.4) 0.66 0.7 (0.2–2.7) 0.64
Adjustment was performed for pregnancy, infant and neonatal hospitalization characteristics. Pregnancy characteristics included prenatal corticosteroid treatment,
multiple pregnancies, hypertension during pregnancy, premature rupture of membranes .24 h, and cesarean section. Mother characteristics included health insurance
for low financial income and upper socio-demographic level. Infant characteristics included GA, birthweight, small for GA, gender. Neonatal hospitalization
characteristics included surfactant therapy, maternofetal sepsis, nosocomial sepsis, bronchopulmonary dysplasia, hemodynamic failure and patent ductus arteriosus
requiring treatment.
doi:10.1371/journal.pone.0030900.t004
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PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e30900Figure 2. Changes in mean serum unconjugated bilirubin levels (SBL) during the first week of life in relation to birthweight. This
figure shows three graphs: (1) the upper graph concerns infants with birthweight under 1500 g; (2) the intermediary graph concerns infants with
birthweight between 1001 and 1500 g, and (3) the lower graph concerns the smallest infants (under 1001 g). Each graph is composed by four curves:
three curves representing changes in mean SBL in infants of the first tertile (line a), second tertile (line b) and third tertile (line c). The fourth curve
(dotted line or line d) represents the 95
th percentile of SBL in infants with an optimal neurological outcome at 2-year corrected age.
doi:10.1371/journal.pone.0030900.g002
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infants with birthweight under 1001 g, those with elevated max-
SBLs had a higher risk of developing impaired functional outcome,
than those with low max-SBLs. However, only an interventional
controlled trial could confirm this observation.
On the other hand, the strength of this retrospective report is
that it was performed on a large sample and the follow-up rates
were high.
Given the lack of validation for phototherapy guidelines in
VLBW infants, our study raised critical questions that could affect
daily clinical practice [13]. Until now, only one study analyzed the
effect of Maisels’ recommendations on neurological outcome [8]. In
this study, among a population of infants under 1500 g or born
before 32 weeks of gestation, the authors found a significant
differencein2-yearneurodevelopmentaloutcome thatdepended on
the infants’ maximal total bilirubin levels. Nevertheless, the lack of
transfontanellar ultrasound assessment could bias the results [8,10].
In our cohort, the presence of brain lesions did not differ among the
three groups, and no relationship between max-SBL and neurode-
velopmental outcome was detected. However, the characteristics of
the three tertiles differed widely, with younger and smaller infants in
the first tertile. Although no difference was found among the groups
in relation to outcome, we cannot exclude the possibility that we
failed to adjust for all the risk factors associated with neonatal
characteristics. The work reported by Oh et al. revealed an
association between hyperbilirubinemia and poor outcome in
unstable infants [12]. Nevertheless, only one sample (at five days
of age) was collected, and the phototherapy procedure was different
for each infant, taking into account that the cohort was built from a
precedent study assessing two differentphototherapy strategies [21].
Among infants weighing less than 1000 g, the difference in
outcome suggested that a revision of Maisels’ recommendations
could be proposed, consisting in a decrease of the SBLs threshold.
Because of physiological particulars and many comorbidity factors
[3–4], it is difficult to define guidelines for starting phototherapy in
VLBW infants. One validated method consists of analyzing data in
infants with optimal outcome and then defining norms [22]. To
determine the most adapted SBL for starting phototherapy in
infants under 1001 g, we compared the 95
th percentile of SBLs in
infants with optimal neurological outcome in relation to
birthweight. The maximal level of these 95
th percentile curves
differed by 26 mmol/L between infants under 1001 g (170 mmol/l
or 10 mg/dL) and those with a birthweight between 1001 and
1500 g (196 mmol/l or 11.5 mg/dL). Consequently, a reduction of
26 mmol/L (1.5 mg/dL) from Maisels’ threshold can be suggested
for infants under 1001 g, i.e., 114 mmol/L (6.7 mg/dL) rather
than 140 mmol/L (8.2 mg/dL), when no hemolytic risk factors are
present. A recent report by Moll et al. on two ELBW infants with
kernicterus supports our recommendation, despite supposed
moderate hyperbilirubinemia [13].
Intensification of phototherapy in younger, premature infants is
subject to debate. In 1992, O’Shea et al. studied the relationship
between maximal total bilirubin and neurodevelopmental outcome
in infants with birthweight under 1500 g with a total bilirubin
threshold for phototherapy of 86 mmol/L (5 mg/dL) [9]. This
management of hyperbilirubinemia seemed safe and efficient. No
association between maximal total bilirubin and neurodevelopmen-
tal outcome at 1-year corrected age was found. Morris et al.
comparedaggressiveandconservative phototherapyin1,974ELBW
infants [21], in whom aggressive phototherapy was started for total
bilirubin levels higher than 86 mmol/L (5 mg/dL), and conservative
phototherapy was started for total bilirubin levels higher than
137 mmol/L (8 mg/dL) (subgroup 501–750 g) or 171 mmol/L
(10 mg/dL) (subgroup 751–1000 g). The rate of death or neurode-
velopmental impairment was not significantly reduced by aggressive
phototherapy. Conversely, aggressive phototherapy was associated
with increased mortalityininfants withbirthweightbetween 501and
750 g. The reduction of antioxidant protection in aggressive
phototherapy could explain this result, as bilirubin presents
antioxidant effects [2] and phototherapy may cause oxidative injury
by photodegradation of antioxidant molecules [23–24].
Thus, the difference in neurodevelopmental outcome among
infants weighing less than 1001 g in our study could be due to the
differences in max-SBL and to the duration of phototherapy. The
infants with higher max-SBL and, consequently, with a more
important exposure to phototherapy, could present a deficit in
antioxidant components at the origin of a poorer neurodevelop-
mental outcome. The difference in impaired functional outcome in
infants weighing under 1001 g was very significant when we
compared them with those with high max-SBLs (third tertile) and
those with moderate max-SBLs (second tertile). Lower SBLs in the
first tertile could have limited the protective antioxidant effect of
bilirubin and reduced the difference in the third group.
In conclusion, we did not observe any difference in impaired
functional outcome between the three tertiles of max-SBL, except
for infants under 1001 g. Although there are inherent limits to this
type of observational studies, our data tend to validate Maisels’
recommendations in the global population of neonates born before
33 weeks of gestation, except for infants with birthweight lower
than 1001 g, suggesting the necessity for a revision of the
phototherapy threshold for infants with VLBW.
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